Guanfacine Tablet, Extended Release
Product Images NDC 51407-952

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 51407-952). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-952-01ol (Guanfacine ER Tablets USP 1mg)

This is a description of a pharmaceutical product in tablet form containing 1 mg of guanfacine. The tablets are not meant to be crushed, chewed, or broken before swallowing. The pharmacist is advised to dispense patient information with each prescription. The package contains 100 tablets, and the usual dosage instructions can be found inside. It is recommended to keep the medication out of reach of children and store it at 20° to 25°C (68 to 77°F). The product is child-resistant and marketed by GSMS, Incorporated in Camarillo, California, USA.*

FDA Label Image

51407-953-01ol (Guanfacine ER Tablets USP 2mg)

This is an excerpt from a medication label for Guanfacine Extended-Release Tablets, USP. Each tablet contains 2 mg of Guanfacine as Guanfacine Hydrochloride USP. It is important not to crush, chew, or break the tablets before swallowing. The usual dosage instructions are provided in the insert. The package is child-resistant and should be stored at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F) in a controlled room temperature environment. Pharmacist instructions include dispensing patient information to each patient. This medication is produced by GSMS, Incorporated.*

FDA Label Image

51407-954-01ol (Guanfacine ER Tablets USP 3mg)

The text contains information about Guanfacine Extended-Release Tablets, each tablet containing 3 mg of guanfacine hydrochloride USP. The tablets should not be crushed, chewed, or broken before swallowing. The usual dosage information can be found in the package insert. The package is child-resistant and should be kept out of the reach of children. It is recommended to store the medication at 20° to 25°C (68" to 77°F). The product is distributed by GSMS, Incorporated, in Camarillo, CA, USA. This package is in English, licensed for sale in the USA, and was last revised on 02/26.*

FDA Label Image

51407-955-01ol (Guanfacine ER Tablets USP 4mg)

This is a description for a pharmaceutical product. It is a pack of Guanfacine Extended-Release Tablets, with each tablet containing 4 mg of guanfacine. The tablets should not be crushed, chewed, or broken before swallowing. The package is child-resistant and should be kept out of the reach of children. The recommended storage temperature is 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F). The product is marketed by GSMS, Inc. from Camarillo, CA, USA and is a product of Spain. The package includes 100 tablets and is for prescription use only.*

FDA Label Image

Figure2 (Guanfacine 2figure)

FDA Label Image

Figure 3 (Guanfacine 3 Figure)

This text mentions the comparison of pharmacokinetic parameters (Cmax and AUC) between Oral Methylphenidate and Lisdexamfetamine Dimesylate. It seems to be discussing the fold change and 90% confidence interval associated with the interaction between these drugs. It also indicates a comparison in changes relative to a reference.*

FDA Label Image

Figure1 (Guanfacine Figure 1)

FDA Label Image

Figure 4 (Guanfacine Figure4)

This text provides data related to the treatment failure over a period of time. It includes numbers representing days, percentages, and other values. The information seems to be part of a study or research related to treatment outcomes.*

FDA Label Image

Structure (Guanfacine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.